Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxalta | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Baxalta

Revenues up 5% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta
 
4Q Revenues: $1.8 billion (+5%)
 
4Q Earnings: $95 million (earnings were $763 million 4Q14)
 
FY Revenues: $6.1 billion (+3%)
 
FY Earnings: $956 million (-47%)
 
Comments: Hematology revenues were $1.0 billion in the quarter, down 2%. Immunology revenues were $680 million, up 8%. Oncology revenues were $53 million from the acquisition of ONCASPAR (pegaspargase) leukemia portfolio from Sigma-Tau. Results include after-tax special items totaling $292 million, primarily for asset repayment, expenses associated with the company’s separation from Baxter International, and certain business development and collaboration-related items.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters